STRN: A Potential Drug Target for Psychiatric Disorders (G6801)
STRN: A Potential Drug Target for Psychiatric Disorders
STRN, or Sodium Channel Receptor, is a protein that is expressed in the brain and plays a crucial role in the regulation of electrical activity in the nervous system. It is composed of four subunits, A, B, C, and D, and is expressed in different brain regions throughout the adult brain. The STRN is involved in the regulation of various physiological processes, including neuronal excitability and synaptic plasticity.
STRN has been identified as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Its involvement in these disorders has led to a growing interest in the study of its potential therapeutic potential.
One of the main reasons for the potential therapeutic impact of STRN is its involvement in the regulation of neuronal excitability.STRN is involved in the regulation of the rapid and slow inward current (RAS and SAS), which are responsible for the resting membrane potential of neurons. The RAS and SAS currents are generated by the opening and closing of ion channels in the neuron, and they play a crucial role in the regulation of neuronal excitability.
STRN has been shown to play a role in modulating the RAS and SAS currents. Studies have shown that the expression of STRN is affected by various neurotransmitters, including dopamine, which is known to play a role in modulating the RAS current. Additionally, pharmacological agents that can modulate the activity of STRN have been shown to have therapeutic effects on various neurological disorders.
Another therapeutic potential application of STRN is its role in synaptic plasticity.STRN is involved in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt over time. This is important for the development and progression of various psychiatric disorders , including Alzheimer's disease.
STRN has been shown to play a role in modulating synaptic plasticity by regulating the release of neurotransmitters, such as dopamine and glutamate. Studies have shown that the expression of STRN is affected by various environmental factors, including stress, diet, and exercise, which can affect the regulation of synaptic plasticity.
In addition to its role in neuronal excitability and synaptic plasticity, STRN is also involved in the regulation of other physiological processes that are important for the health and function of the brain. For example, STRN is involved in the regulation of ion homeostasis, which is important for maintaining the stability of the brain's electrolyte balance. Additionally, STRN is involved in the regulation of neuroendocrine systems, which are responsible for the production and release of hormones that regulate various physiological processes in the body.
STRN has also been shown to play a role in the development and progression of various psychiatric disorders. Studies have shown that the expression of STRN is affected by various psychiatric disorders, including Alzheimer's disease and depression. Additionally, pharmacological agents that can modulate the activity of STRN have been shown to have therapeutic effects on these disorders.
In conclusion, STRN is a protein that is involved in the regulation of various physiological processes that are important for the health and function of the brain. Its involvement in the regulation of neuronal excitability and synaptic plasticity makes it a potential drug target for various neurological and psychiatric disorders. Additionally, its involvement in the regulation of other physiological processes makes it important for the health and function of the brain. Further research is needed to fully understand the role of STRN in the regulation of neural activity and the development and progression of various psychiatric disorders.
Protein Name: Striatin
Functions: Calmodulin-binding protein which may function as scaffolding or signaling protein and may play a role in dendritic Ca(2+) signaling
More Common Targets
STRN3 | STRN4 | STS | STT3A | STT3A-AS1 | STT3B | STUB1 | STUM | STX10 | STX11 | STX12 | STX16 | STX16-NPEPL1 | STX17 | STX17-DT | STX18 | STX18-AS1 | STX18-IT1 | STX19 | STX1A | STX1B | STX2 | STX3 | STX4 | STX5 | STX5-DT | STX6 | STX7 | STX8 | STXBP1 | STXBP2 | STXBP3 | STXBP4 | STXBP5 | STXBP5-AS1 | STXBP5L | STXBP6 | STYK1 | STYX | STYXL1 | STYXL2 | SUB1 | SUB1P1 | Succinate Dehydrogenase Complex | Succinate-CoA ligase (ADP-forming) | SUCLA2 | SUCLG1 | SUCLG2 | SUCLG2-DT | SUCLG2P2 | SUCNR1 | SUCO | SUDS3 | SUFU | SUGCT | SUGP1 | SUGP2 | SUGT1 | SUGT1P1 | SUGT1P2 | SUGT1P3 | SUGT1P4-STRA6LP-CCDC180 | SULF1 | SULF2 | Sulfotransferase | SULT1A1 | SULT1A2 | SULT1A3 | SULT1A4 | SULT1B1 | SULT1C2 | SULT1C3 | SULT1C4 | SULT1C5P | SULT1D1P | SULT1E1 | SULT2A1 | SULT2B1 | SULT4A1 | SULT6B1 | SUMF1 | SUMF2 | SUMO activating enzyme complex | SUMO1 | SUMO1P1 | SUMO1P3 | SUMO2 | SUMO2P21 | SUMO2P3 | SUMO2P6 | SUMO2P8 | SUMO3 | SUMO4 | SUN1 | SUN2 | SUN3 | SUN5 | SUOX | Superoxide dismutase (SOD) | Suppressor of cytokine signaling (SOCS)